This invention relates to substituted thiazoles of formula I:wherein: L is selected from the group consisting of -NHC(X)-, -C(X)NH-, -NHC(X)NH-, -C(X)-, -C(X)NH-alkylene- and -NHC(X)-alkylene-, where X is oxygen or sulfur and Q is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic, pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and their use as VEGFR2 (vascular endothelial growth factor receptor 2) kinase inhibitors and in the treatment of diseases capable of treatment by a VEGFR2 kinase inhibitor, particularly cancer.
